Patients with perianal fistulizing Crohn's disease have a poor prognosis because these lesions do not heal well. We evaluated the effects of local administration of bone marrow-derived mesenchymal stromal cells (MSCs) to these patients from healthy donors in a double-blind, placebo-controlled study.
INTRODUCTION
Perianal fistulizing Crohn's disease (CD) remains a significant clinical challenge greatly affecting patients' quality of life due to pain, discharge, and abscess formation. 1 At least 23-26% of CD patients develop perianal fistulas within 20 years after diagnosis. 2, 3 Achieving complete fistula healing is often a long process accompanied by multiple relapses. Patients frequently fail to respond to current medical options including antibiotics, immunosuppressive agents and anti-tumor necrosis factor (TNF) biologicals. [4] [5] [6] To prevent abscess formation, surgical placement of non-cutting setons is often required. In more severe cases, fecal diversion is needed to attenuate perianal disease. 7 The ultimate treatment goal is complete fistula healing without sphincter damage. Unfortunately, despite the best available therapies, durable remission rates of complex perianal fistulas remains low at 37.0%. 8 An emerging therapeutic approach is the use of mesenchymal stromal cells (MSCs). These are non-hematopoietic multipotent cells able to downregulate immune responses and promote tissue healing. It has been reported that human MSCs are able to inhibit generation of dendritic cells (DCs) from monocytes, are capable of downregulating expression of presentation-and costimulatory molecules on mature DCs preventing T cell activation, and promote the generation of T regulatory cells (Tregs). [9] [10] [11] [12] [13] [14] Furthermore, MSCs participate in tissue repair processes providing a strong rationale for the use of these cells as a treatment for perianal fistulizing CD. Recently, phase I and II clinical trials have shown promising results on the healing rates of perianal fistulas. [15] [16] [17] [18] [19] [20] Locally injected MSCs demonstrated 69-82% fistula healing. [16] [17] [18] 20 MSCs used in these trials were predominantly harvested from autologous adipose tissue and were reported to be a safe and feasible option. However, autologous MSCs are not immediately available upon request since isolation and expansion of MSCs to sufficient numbers of cells requires weeks which results in treatment delay. In addition, the possibility of disease-related effects on autologous MSCs must be taken into account. Therefore, we used allogeneic MSCs derived from bone marrow aspirates of healthy donors. Until now, no similar placebo-controlled trials have been performed. We report the results of a randomized, double-blind, placebo-controlled, dose-escalating clinical trial evaluating the safety and efficacy of allogeneic bone marrow-derived MSCs additional to surgical treatment of refractory perianal fistulizing CD.
PATIENTS AND METHODS

Patient selection and study design
Eligible patients were men and women of at least 18 years of age with actively draining perianal fistulizing CD refractory to conventional therapies meaning that at some time during the perianal fistula disease course, patient must have received anti-TNF agents and, in addition, antibiotics, steroids, thiopurines, methotrexate, surgery or combinations thereof which did not result in an adequate treatment response. Eligible patients had to have 1-2 internal openings and 1-3 fistula tracts. Further criteria for inclusion were: diagnosis of CD at least 3 months before enrolment, CD Activity Index (CDAI) score of <250 at screening and baseline, stable dose of current drugs (5-ASA and steroids ≥ 4 weeks; immunosuppressive drugs ≥ 8 weeks; anti-TNF agents ≥ 8 weeks) which were continued during the entire study period. Patients were not allowed to use antibiotics after inclusion in the trial. Furthermore, patients were not eligible if there was need for immediate surgery (obstruction, strictures or abscesses); pregnancy; breastfeeding; or when they did not use adequate contraception. Further exclusion criteria were: evidence of any infection needing antibiotic treatment; rectovaginal fistulas; complex perianal fistulas with more than 2 internal openings; evidence of acute perianal infection; and presence of an anal or rectal stricture hindering the surgeon to adequately perform the intervention; active luminal disease; renal-or hepatic failure; use of any investigational drug within 1 month prior to screening or within 5 half-lives of the investigational agent (whichever is longer); not able or willing to undergo magnetic resonance imaging (MRI); change in concomitant medication; documented HIV infection; active hepatitis B, C or tuberculosis; an opportunistic infection within 6 months prior to screening or a serious infection in the previous 3 months; malignancy within the past 5 years; or a history of lymphoproliferative disease.
Screening assessment included physical examination, laboratory measurements (incl. hepatitis B, C, HIV serology, PCR-CMV and PCR-EBV, IFNɣ release assay (IGRA) and β-hCG), stool cultures (incl. Clostridium difficile toxin A and B) and a chest X-ray to rule out the presence of tuberculosis. MRI was performed at screening to evaluate the exact anatomy and internal opening(s) of the fistula(s), their relation to the sphincters and the presence of abscesses. When MRI results were non-conclusive, an examination under anesthesia (EUA) was performed to determine the exact location of the fistula(s). Abscesses > 2 cm were surgically drained at EUA. Subsequently the patient was re-screened before proceeding to inclusion or exclusion. At baseline, sigmoidoscopy was performed to rule out luminal inflammation. Perianal fistulas were classified using the 'simple or complex' classification. 21 All patients who did not have setons in situ after inclusion in the study received temporarily setons to ensure that the internal opening was still open at time of surgical intervention.
These setons were removed during the surgical intervention.
The study overview is shown in figure 1. Patients were enrolled in a double-blind, randomized 5:2 fashion to receive locally either 1x10 7 (group 1), 3x10 7 (group 2) or 9x10 7 (group 3) MSCs or 0.9% NaCl/5% human albumin solution with no cells (placebo group).
Randomization was performed at the Immunohematology and Blood Transfusion department by a researcher who did not have any contact with and any knowledge about the included patients. The study was posted on ClinicalTrials.gov. under number NCT01144962. Dose escalation took place after all subjects in the previous group were treated and the Data Safety Monitoring Board (DSMB) reviewed the safety outcomes and approved study continuation. The study was approved by the Medical Ethical Committee of the Leiden University Medical Center (LUMC) and the Central Committee on Research involving Human Subjects (CCMO, The Hague, Netherlands) and all patients gave written informed consent. All data was collected in the LUMC. 
Preparation of MSCs
MSCs were prepared from 5 different donors from 50-100 mL bone marrow aspirates of healthy donors without a history of cancer or hereditary diseases and after written informed consent. Cells from different donors were processed separately and MSC yield from 1 donor was sufficient to create batches of 1x10 7 , 3x10 7 Two weeks before the intervention was planned, the patient was randomized to receive either MSCs or placebo ( figure 1 ). When the patient was randomized to receive MSCs, cryopreserved MSC half product was thawed, washed and replated in MSC culture medium for expansion to sufficient number of cells (maximally 2 passages). MSCs were then harvested and suspended at study group-dependent final concentrations in 5 mL of 0.9% NaCl/5% human albumin solution divided over 2 syringes with 2.5 mL cell suspension each.
This end product was released when it met the following criteria: >90% of the cells formation. The rectum was also evaluated at week 12 during sigmoidoscopy. The primary safety endpoint was the incidence of (serious) adverse events at week 12. Toxicity grade of adverse events was determined using the Common Terminology Criteria for Adverse Events (CTCAE version 3.0). Secondary endpoints included the incidence of surgical intervention and infections at week 12 and 24.
Efficacy
To evaluate fistula healing, a physician assessed blindly fistula discharge by gentile finger pressure at the external opening. In addition, patients underwent a MRI at week 12. Fistula 
Laboratory methods for supportive research
Homogenates were prepared from rectal biopsies taken at endoscopy at baseline and week 12 (n = 21), and curettage material obtained at surgical intervention (n = 20) with a Potter- The mean fistula duration was 5.5 years (range, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] , most were complex fistulas with a transsphincteric route (both 65.2%) and the internal opening was predominantly observed The primary endpoints were met in all patients. For the secondary endpoints, one patient in group 2 was not able to undergo week 12-endoscopy and one patient in group 2 did not complete the week 24 questionnaires. Week 0
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Cytokine levels in rectal biopsies and fistula curettage material
In order to study MSC healing mechanisms and avoiding invasive fistula biopsies which would compromise fistula healing, we compared rectum cytokine levels (baseline and week 12) with fistula curettage obtained at surgery. Mean levels of IL-8, IL-1β and IL-6 in the rectal biopsies were similar at baseline and after surgical intervention at week 12 (figure 6), irrespective of treatment. No differences in the levels of these cytokines were observed at week 12 after treatment with 1x10 7 , 3x10 7 or 9x10 7 , or placebo (data not shown), which matched with the stable CDAI, CDEIS and SES-CD scores during the study period. Mean levels of IL-8, IL-1β and IL-6 were overall significantly higher in the fistula curettage material compared to the mean levels in the rectal biopsies at either week 0 or 12 (all P < 0.0001).
Cytokine levels of TNF, IL-10 and IL-12p70 were below the detection rate in all samples. 
DISCUSSION
Recently, several papers have reported efficacy of local treatment of refractory perianal fistulizing CD with MSCs. [15] [16] [17] [18] [19] [20] However, none of these trials was really placebo-controlled.
Therefore we performed an early phase II, double-blind, placebo-controlled, randomized study addressing the use of allogeneic bone marrow-derived MSCs in the treatment of refractory perianal fistulizing CD. We showed that local administration of allogeneic bone marrow-derived MSCs was safe and feasible in patients with refractory perianal fistulizing CD.
Local treatment with lower dosages of MSCs resulted in higher fistula healing rates compared to placebo which seems to be a dose-dependent response as administration of 3x10 7 MSCs resulted in high fistula healing rates and 9x10 7 in rates similar to placebo treatment. Previously, the importance of MSC cell dose was described in both a sheep model of myocardial infarction and in humans with ischemic cardiomyopathy. 22, 23 In both papers, a Although MSC-treatment was effective in group 1 and 2, quality of life measured by sIBDQ and SF-36, did not increase during the study. At baseline PDAI scores were lower than expected for patients with perianal fistulizing CD. Both quality of life and PDAI scores consist partially of questions on restrictions in daily activities. All these questions were answered negative, indicating that our patients did not experience restrictions in their daily life due to the fistulas, probably because after a mean 5.5 years they were 'used to' having fistulas with continuously discharge and pain, and managed to continue with their activities despite the daily discomfort. In addition, abscesses larger than 2 cm were drained before inclusion in the trial resulting in less anal pain and thus in lower PDAI scores and possibly a better quality of life.
In our study we used allogeneic MSCs harvested from bone marrow of healthy donors. One of the advantages of allogeneic MSCs is the possibility to generate a stock with 'off-theshelf' treatment potential without the requirement to expand autologous MSCs for weeks before a patient can be treated. Immediate availability of MSCs for the treatment of fistulas is warranted as the development of abscesses requires surgery and results in a reduced quality of life. In addition, MSCs can be harvested from healthy young donors with a higher yield compared to older donors and possessing a higher regenerative and immunomodulatory potential, thereby also avoiding possible disease-related effects on the autologous MSCs. [24] [25] [26] Similar to autologous MSCs, in this study allogeneic MSCs were observed to be safe. During the study period, none of the included patients reported adverse events related to MSC injection.
One of the concerns of cell-based therapy is the safety regarding malignant transformation of the administered cells. While no neoplasia were observed during the long-term follow-up study 27 , a recently published meta-analysis 14 papers 28 did show occurrence of malignancies but only in patients with previous or current malignancies, no formation of de novo tumours were reported. In our study, only one patient (in group 1) developed an adenocarcinoma but it was localized in the cecum. In our patient, the rectum was and remained completely normal at baseline and follow-up endoscopy of the local administration site. The local injection of MSC in this regard argues against causing cancer at a different site. Also, the patient developed this cancer more than 15 months after MSC-therapy. Adult MSCs are reported to have a very limited lifespan in vivo; such a late cancer development seems not compatible with a direct relation to MSC administration. Lastly, the patients' uncle died from colon cancer at age 42 suggesting a hereditary component.
Although the recently published results on MSC treatment for perianal fistulizing CD are promising, there are substantial differences in the origin and preparation of MSCs, and techniques of administration among these studies, making it difficult to compare. [15] [16] [17] [18] [19] [20] We believe that an important step to achieve MSC efficacy is the removal of the epithelial layer present in long-standing perianal fistulas hindering fistula healing. In addition, attention must be paid to the closure of the internal opening since that is the place where the fistula has emerged and prohibits fecal contamination of the treated fistula tract. For this reason, this was also the location of MSCs injection.
The mechanism(s) by which the administered MSCs exert their action was not studied in our trial. MSCs possess a broad range of immunomodulatory properties interfering in both the innate and adaptive immune system. 29, 30 Pre-and post-MSC administration, biopsies with subsequent analysis of infiltrates could shed light whether the immunosuppressive effects of MSCs in vitro can be confirmed. It has been reported that the percentage of Tregs was increased in both rectal biopsies and peripheral blood 12 months after intrafistular MSC treatment, compared to baseline, suggesting a systemic effect of injected MSCs. 18 In our patients, active CD was only localized in the fistula with luminal disease in remission as reflected by the stable CDAI, CDEIS and SES-CD during the entire study period. This was also reflected by the stable and low levels of inflammatory cytokines in the biopsies.
Interestingly, examining the mean levels of proinflammatory cytokines IL-8, IL-1β and IL-6 in the fistula curettage material obtained at surgical intervention revealed baseline fistula cytokine levels were at least significantly higher as found in rectal biopsies either in week 0 or 12. Unfortunately, no follow-up material of the fistulas could be studied.
In conclusion, local administration of allogeneic bone marrow-derived MSCs was found to be safe and feasible in patients with refractory perianal fistulizing CD. Local treatment with 3x10 7 MSC showed superior fistula healing compared to placebo, and lower MSC dosage seemed superior to the use of a higher dose.
